DGX

Quest Diagnostics (DGX) reported Q3 2026 adjusted earnings of $3.00 per share (up 15.4% YoY) and revenues of $3.10 billion (up 10% YoY), both beating consensus estimates. The company raised full-year 2026 revenue guidance to $12.065-$12.105 billion and adjusted EPS outlook to $11.25-$11.35.

Despite strong results, DGX shares fell 1.6% in pre-market trading. Operating margins improved 40 basis points to 16.7%, driven by strong testing demand and organic requisition volume growth of 14.4%.

Quest Diagnostics reported Q3 2026 earnings of $3.00 per share, beating consensus estimates of $2.85 and surpassing revenue expectations at $3.1 billion. The company has beaten EPS estimates in four consecutive quarters.

However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical - Outpatient and Home Healthcare industry ranks in the top 31% of Zacks industries.